This inventor holds 4 USPTO granted patents and 4 published patent applications and 2 EPO patents. Top assignees: Nanyang Technological University, Singapore Health Services Pte Ltd. Active years: 2018-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2018-2026
Title: Innovations by Jayaganesh V Natarajan
Introduction
Jayaganesh V Natarajan is a notable inventor based in Singapore, recognized for his contributions to ocular drug delivery systems. He holds three patents that showcase his innovative approach to treating anterior segment eye diseases.
Latest Patents
One of his latest patents is titled "Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases." This invention involves the use of nanoliposomes that encapsulate tacrolimus, a hydrophobic drug, within lipid bilayers. The formulation aims to provide effective prophylaxis and treatment for anterior segment ocular diseases. Another significant patent is the "Liposomal formulation for ocular drug delivery," which focuses on a liposomal formulation that includes a prostaglandin drug. This formulation is designed to enhance the delivery of ocular medications, ensuring better treatment outcomes for patients.
Career Highlights
Jayaganesh has worked with esteemed institutions such as Nanyang Technological University and Singapore Health Services Pte Ltd. His work in these organizations has contributed to advancements in medical technology and drug delivery systems.
Collaborations
He has collaborated with notable professionals in his field, including Subramanian Venkatraman and Yin Chiang Freddy Boey. These collaborations have further enriched his research and development efforts.
Conclusion
Jayaganesh V Natarajan's innovative work in ocular drug delivery systems highlights his significant contributions to the field of medicine. His patents reflect a commitment to improving treatment options for patients with eye diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile